8-K: EBR Systems Reports Strong Q4 2025 Commercial & Clinical Progress

EBR Systems announced significant commercial and clinical advancements in Q4 2025, including doubled case volumes and positive preliminary revenue estimates.

Summary

• Commercial momentum continued through Q4 2025, with case volumes doubling from Q3 2025.
• The WiSE System was successfully implanted in 18 commercial patients during Q4 2025, reaching 30 implants for the combined pilot phase and Limited Market Release.
• Preliminary unaudited Q4 2025 revenue is expected to be in the range of US$870K and US$935K.
• Total preliminary unaudited 2025 revenue is expected to be in the range of US$1,552K and US$1,617K.
• An incremental 9 purchase agreements were signed and 11 additional physicians were trained in Q4 2025 to support the adoption of WiSE.
• The WiSE-UP post-approval study commenced with initial patient enrolments.
• The TLC-AU feasibility study commenced, with the first patient enrolled in Australia.

Sentiment

Score: 8

Explanation: The filing reports strong commercial and clinical progress, including doubled case volumes and positive preliminary revenue estimates. The commencement of new clinical studies, particularly TLC-AU, indicates significant potential for market expansion. While financial results are preliminary, the overall tone and reported metrics are highly positive for the company's growth trajectory.

Positives

• Case volumes for the WiSE System doubled from Q3 2025 to Q4 2025.
• Successful implantation of the WiSE System in 18 commercial patients during Q4 2025, contributing to a total of 30 implants for the combined pilot phase and Limited Market Release.
• Preliminary Q4 2025 revenue is expected to be strong, ranging from US$870K to US$935K.
• Preliminary total 2025 revenue is projected between US$1,552K and US$1,617K.
• An additional 9 purchase agreements were signed with target centers, and 11 new physicians were trained to implant the WiSE System in Q4 2025.
• Commencement of the WiSE-UP post-approval study with initial patient enrolments, generating real-world outcomes data.
• Commencement of the Totally Leadless CRT (TLC-AU) feasibility study in Australia, which has the potential to significantly expand the total addressable market by targeting de novo CRT patients (approximately 75% of the CRT market).

Negatives

• Preliminary financial results are unaudited and subject to change upon completion of financial closing procedures and audit.

Risks

• Actual financial results may differ from preliminary estimates due to inherent risks and uncertainties in the business, including audit adjustments and other developments.
• Preliminary financial results are not a substitute for audited financial information prepared in accordance with U.S. generally accepted accounting principles.
• Forward-looking statements involve known and unknown risks, uncertainties, contingencies, and other factors, many of which are beyond the Company's control, that could cause actual results to differ materially.
• Risks are described in more detail in the most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC.
• Holders of EBR's ASX-traded CHESS Depositary Interests (CDIs) are unable to sell them into the US or to a US person unless the re-sale is registered under the Securities Act or an exemption is available.

Future Outlook

The company remains focused on disciplined execution and building the evidence base required to support broader adoption of the WiSE System. The TLC-AU study, evaluating totally leadless CRT in de novo patients, has the potential to significantly expand EBR's total addressable market, establishing WiSE as a potential first-line option for patients requiring CRT.

Management Comments

• "In Q4 2025, we continued to make solid progress across both our commercial and clinical programs. Case volumes increased meaningfully, reflecting growing physician experience and expanding site readiness." John McCutcheon, President & Chief Executive Officer.
• "Additionally, we advanced important clinical initiatives, including the commencement of the WiSE-UP post-approval study and the first patient enrolled and implanted in the TLC-AU feasibility study." John McCutcheon, President & Chief Executive Officer.
• "With ongoing progress in our Limited Market Release, we remain focused on disciplined execution and building the evidence base required to support broader adoption of the WiSE System." John McCutcheon, President & Chief Executive Officer.
• "This Veteran with heart failure had previously undergone an unsuccessful attempt at conventional cardiac resynchronization therapy (CRT) upgrade due to anatomical limitations that precluded coronary sinus lead placement, rendering standard transvenous resynchronization therapy infeasible. To achieve effective left ventricular activation, the multidisciplinary team utilized the WiSE system to deliver left ventricular endocardial pacing, providing an alternative resynchronization strategy for a complex clinical presentation." Dr Ram Amuthan, MD, Clinical Cardiac Electrophysiologist.
• "We were honored to perform the 30th WiSE implantation nationally, and to introduce this technology in support of our mission to deliver innovative, high-quality cardiovascular care to the Veteran population." Dr Ram Amuthan, MD, Clinical Cardiac Electrophysiologist.

Industry Context

EBR Systems is developing the world's only wireless cardiac pacing device for heart failure, the WiSE System, which aims to eliminate the need for cardiac pacing leads, a major source of complications in traditional Cardiac Resynchronization Therapy (CRT). The commencement of the TLC-AU study for de novo patients (representing approximately 75% of the CRT market) positions WiSE to potentially become a first-line option, disrupting the conventional lead-based CRT market and addressing a significant unmet need.

Comparison to Industry Standards

• The WiSE System is described as the "worlds only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the hearts left ventricle," offering a potentially superior, more anatomically correct pacing location compared to traditional lead-based CRT systems.
• The technology aims to eliminate the need for coronary sinus leads, which are a major source of complications, effectiveness, and reliability issues in conventional cardiac rhythm disease management.
• The TLC-AU study evaluates totally leadless CRT, combining the WiSE System with an Abbott Aveir DR leadless pacemaker, building on existing FDA-approved labeling for patients with an existing leadless pacemaker. This positions EBR to potentially address the 75% of the CRT market represented by de novo patients, where conventional lead-based systems are currently dominant, offering a novel alternative.

Stakeholder Impact

• Shareholders: Positive impact due to strong commercial momentum, revenue growth, and potential market expansion, indicating future growth prospects and increased shareholder value.
• Patients: Improved access to advanced cardiac resynchronization therapy, especially for those with anatomical limitations or requiring totally leadless solutions, enhancing quality of life and treatment options.
• Hospitals/Physicians: Increased adoption of innovative technology, expanded treatment options for complex heart failure patients, and ongoing training support, potentially leading to better patient outcomes and institutional reputation.
• Employees: Positive outlook due to company growth, clinical advancements, and expanding market presence, potentially leading to job security and growth opportunities.

Next Steps

• Complete the financial close process for the quarter and year ended December 31, 2025.
• Undergo the audit of consolidated financial statements for the year ended December 31, 2025.
• Continue site activations and case scheduling under the Limited Market Release, laying a strong foundation for Q1 2026.
• Continue patient enrolment and follow-up for the WiSE-UP post-approval study (over 300 commercial patients across 50 centers over five years).
• Continue evaluation and patient enrolment in the TLC-AU feasibility study.
• Build the evidence base required to support broader adoption of the WiSE System.

Key Dates

Recommendation

The filing demonstrates significant operational and strategic progress, with commercial case volumes doubling and strong preliminary revenue figures. The initiation of the TLC-AU study, targeting the large de novo CRT market, represents a substantial growth catalyst. The WiSE System's unique leadless technology addresses a critical unmet need in heart failure treatment, positioning EBR Systems for continued market penetration and long-term value creation. The positive clinical and commercial momentum, despite preliminary financials, suggests a strong investment opportunity.

Keywords

Wireless cardiac pacing, heart failure, WiSE System, CRT, cardiac resynchronization therapy, leadless pacemaker, medical device, Q4 2025 results, clinical trials, commercial progress, EBR Systems